Lophius Biosciences is thrilled to announce the successful raising of $7 million in funding, an achievement that underscores our commitment to revolutionizing the diagnostic landscape for infectious diseases. With a mission to transform treatment paradigms and enhance patient management, Lophius has been at the forefront of developing innovative molecular diagnostic solutions specifically designed for life-threatening and highly-contagious infectious diseases. Our core program is dedicated to addressing the significant unmet clinical need in tuberculosis (TB), a global epidemic that currently affects hundreds of millions. By leveraging our proprietary blood-based, multi-marker solution, we aim to achieve a substantial enhancement in TB infection detection compared to existing methodologies. This groundbreaking approach not only promises to improve early diagnosis but also strives to distinguish between active TB disease and latent TB infection, effectively disrupting the current diagnostic framework. Additionally, our commitment to personalized medicine is exemplified through the commercialization of a clinically validated CE marked diagnostic kit tailored to improve management strategies for transplant patients, allowing for individualized CMV disease risk stratification. The funding we have raised will be pivotal in accelerating our research and development efforts, facilitating further advancements in our biomarker combinations, and ultimately enhancing patient outcomes in the global battle against infectious diseases. As we embark on this exciting journey, we are deeply grateful to our investors and partners for their unwavering support and belief in our vision for a healthier future.
Revolutionizing Infectious Disease Diagnosis: Lophius Biosciences Secures $7 Million in Funding for Breakthrough Molecular Solutions
Recently funded 路 $7.0MDomain Services
Get the full Lophius Biosciences company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
